Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1481
Shown on this page
12
Current sort
Recently updated
Campus scope
Massachusetts General Hospital, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Massachusetts General Hospital, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 637–648 of 1,481 matching trials with a site at Massachusetts General Hospital, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 2 Interventional

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

NCT02977780
Status at this site: Recruiting
View directory record Official record
Conditions
Glioblastoma
Interventions
Temozolomide, Neratinib, QBS10072S, Abemaciclib, CC-115
Drug
Lead sponsor
David Reardon, MD
Other
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Not yet recruiting Phase 1 Interventional

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

NCT07278492
Site status not listed — check the official record
View directory record Official record
Conditions
Down Syndrome (DS)
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Not yet recruiting Phase 3 Interventional

COMparison Between Anakinra and Tocilizumab in NORSE - "COMBAT-NORSE"

NCT07281027
Site status not listed — check the official record
View directory record Official record
Conditions
New Onset Refractory Status Epilepticus, New-Onset Refractory Status Epilepticus, Febrile Infection-Related Epilepsy Syndrome (FIRES)
Interventions
Anakinra, Tocilizumab, Standard medical treatment
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
2 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
25
States / cities
Phoenix, Arizona • Aurora, Colorado • New Haven, Connecticut + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

ATEMPT 2.0: Adjuvant T-DM1 vs TH

NCT04893109
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer
Interventions
trastuzumab-emtansine, Trastuzumab SC, Paclitaxel
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
53
States / cities
San Francisco, California • Derby, Connecticut • Fairfield, Connecticut + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

NCT04104776
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
Interventions
Tulmimetostat, Enzalutamide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
22
States / cities
Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Active, not recruiting Phase 1 Interventional

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

NCT03959891
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Fulvestrant, Aromatase Inhibitor, Palbociclib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Not yet recruiting Phase 2 Interventional

(TNX-1500) in Kidney Transplant Recipients

NCT07204080
Site status not listed — check the official record
View directory record Official record
Conditions
Kidney Transplant, Kidney Transplant Failure and Rejection, Immunosuppression, Immunosuppression After Kidney Transplantation
Interventions
TNX-1500, Kidney Transplant
Drug · Procedure
Lead sponsor
Ayman Al Jurdi, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Recruiting No phase listed Observational

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

NCT05489705
Status at this site: Recruiting
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy
Interventions
Mavacamten, Non-mavacamten symptomatic oHCM therapy
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
60
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 48 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Recruiting No phase listed Observational

Prospective Global Registry for the Study of Chronic Total Occlusion Intervention

NCT02061436
Status at this site: Recruiting
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2030
U.S. locations
42
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

Platform Clinical Study for Conquering Scleroderma

NCT06195072
Status at this site: Recruiting
View directory record Official record
Conditions
Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Interventions
Amlitelimab, BI 1015550 (Nerandomilast), Placebo
Drug
Lead sponsor
Scleroderma Research Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
17
States / cities
Duarte, California • La Jolla, California • Santa Monica, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 4:17 PM EDT
Not yet recruiting Not applicable Interventional

Development of a Psychosocial Intervention to Reduce Post Traumatic Stress in Young Adult Survivors of Cancer

NCT07160933
Site status not listed — check the official record
View directory record Official record
Conditions
Post-traumatic Stress Symptoms
Interventions
Psychosocial Intervention for Cancer-Related Post-Traumatic Stress in Young Adults
Behavioral
Lead sponsor
Zeba Ahmad, Ph.D.
Other
Eligibility
18 Years to 39 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 4:17 PM EDT

About this Massachusetts General Hospital institution page

What this page lists
ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Massachusetts General Hospital at any site, browse by condition, or browse by U.S. city.